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Abstract
Purpose: The update of US Pharmacopeia Chapter 797 in
2008 included guidelines stating that single-dose vials (SDVs)
opened and maintained in an International Organization for Stan-
dardization Class 5 environment can be used for up to 6 hours
after initial puncture. A study was conducted to evaluate the cost
of discarding vials after 6 hours and to further test sterility of vials
beyond this time point, subsequently defined as the beyond-use
date (BUD).
Methods: Financial determination of SDV waste included 2
months of retrospective review of all doses prescribed. Addition-
ally, actual waste log data were collected. Active and control vials
(prepared using sterilized trypticase soy broth) were recovered,
instead of discarded, at the defined 6-hour BUD.
Results: The institution-specific waste of 19 selected SDV med-
ications discarded at 6 hours was calculated at $766,000 annually,
and tracking waste logs for these same medications was recorded
at $770,000 annually. Microbiologic testing of vial extension beyond
6 hours showed that 11 (1.86%) of 592 samples had one colony-
forming unit on one of two plates. Positive plates were negative at
subsequent time points, and all positives were single isolates most
likely introduced during the plating process.
Conclusion: The cost of discarding vials at 6 hours was signifi-
cant for hazardous medications in a large academic medical center.
On the basis of microbiologic data, vial BUD extension demon-
strated a contamination frequency of 1.86%, which likely repre-
sented exogenous contamination; vial BUD extension for the tested
drugs showed no growth at subsequent time points and could
provide an annual cost savings of more than $600,000.
Introduction
The future of health care is a topic of ongoing debate in the US
government. Because medication costs constitute a large por-
tion of the budgets of health care organizations, and with con-
tinued development of new molecular entities, there is a need
for all institutions to evaluate operations to identify opportuni-
ties for cost reduction in pharmaceuticals.
Another growing issue gaining significant media attention is
the impact of drug shortages. Although these have always oc-
curred, the number and frequency are worse than in previous
years.1 Chemotherapy drug shortages have been most signifi-
cant with regard to patient impact.2 Patients have had therapies
delayed or have used second-line regimens, because preferred
medications were unavailable for use. Methodologies to con-
serve medications are needed to treat as many patients as safely
as possible.
US Pharmacopeia (USP) Chapter 797, first released in
2004, established federally enforceable practices for preparation
of compounded sterile preparations (CSPs). Many in the phar-
macy community were not compliant with these regulations
when developed. A survey conducted after the release of USP
797 demonstrated that only 35% of respondents had a
compliant cleanroom.3 In addition to organizations planning a
new cleanroom, there were other recurring costs that required
budgeting, including the personal protective equipment re-
quired for daily wear by individuals preparing CSPs and the
equipment used for environmental monitoring. Over 75%
of hospitals reported increasing their pharmacy budget to
accommodate new purchases.
USP 797 has exposure limitations based on air quality
set by the International Organization for Standardization (ISO)
for medication vials once punctured.4 Although the original
USP 797 differentiated single- (SDVs) from multiple-
dose vials (MDVs), it did not specify exposure times or permit
the reuse of the vial. The 2008 update included new recommen-
dations for SDV use, stating that SDVs opened and maintained
in an ISO Class 5 environment may be used for up to 6 hours
after initial puncture.4 For purposes of this discussion, the ex-
posure limitation is referred to as the beyond-use date (BUD).
Standards used to measure bacterial growth are described in
USP Chapter 51 (Antimicrobial Effectiveness Testing).
This states that lack of bacterial growth is defined as no more
than a 0.5-log10 unit increase compared with the previously
measured value.5 For example, if the properties of a bacteria
include a lag time of 6 hours and a population doubling of 30
minutes, then an inoculation of this bacteria in a growth me-
dium of soybean-casein digest would result in a typical micro-
bial growth curve. If 10 colony-forming units (CFUs) per
milliliter were introduced into a vial of growth medium at time
0 and incubated appropriately, time 6 hours would demon-
strate lack of growth (still 10 CFUs per mL), but time 9 hours
would demonstrate microbial growth (640 CFUs per mL). This
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is because 640 CFUs per milliliter is greater than a 0.5-log10
unit increase from the previously measured value. In this sce-
nario, first penetration of the vial, leading to microorganism
entry, would not demonstrate any microbial growth if a 6-hour
BUD were adhered to and these assumptions were observed.6
This standard was used to define growth or no growth in this
study. If one CFU was identified during plating, but subse-
quent sampling showed no CFUs, there was no growth in the
vial, suggesting the colony was introduced during the plating
process.
The SDV 6-hour BUD was based on a standard microbial
growth curve.7 However, whether systems or different condi-
tions can prevent microbiologic contamination of the contents
of a vial or if all medications allow this standard growth has not
been evaluated. Additionally, the cost of the remaining medi-
cation has not been estimated and could be substantial. This is
particularly of note with regard to chemotherapy, in which
medication dosing is a factor of weight or body-surface area and
usually does not align with manufactured vial sizes. A prior
study conducted in Belgium assessed three scenarios for dis-
carding hazardous drug vials: discarding the vial after one CSP,
using the vial until the end of the day, and using the vial until
chemical expiration date or stability of the drug.8 Although
none of these scenarios were directly applicable to the proce-
dures recommended in USP 797, the results demonstrated
the economics associated with drugs remaining in the vials.
Theoretic change in practice from the third to the second sce-
nario resulted in a drug cost increase of 6%, and change from
the third to the first scenario resulted in an increase of 13%. If
a process could be found supporting the safe extension of the
vial BUD without an increased risk to the patient, drug cost
savings could be realized.
Closed-system transfer devices (CSTDs) are used to prevent
employee exposure to chemotherapy. Studies have demon-
strated that settings in which chemotherapy is prepared and
administered have documented environmental contamina-
tion.9 The implementation of CSTDs can lead to lower em-
ployee uptake and exposure to chemotherapy.10 De Prijck et
al11 tested the concept of potential for microbiologic ingress in
vials during simulated manipulations with contamination arti-
ficially placed on the stopper. After the testing of five different
devices or methods used in chemotherapy preparation, one pro-
cess (PhaSeal; Carmel Pharma, Columbus, OH) introduced the
lowest amount of microorganisms into the vial and was statis-
tically better than all other processes.11 It is important to note
that contamination was detected in the vial using a CSTD and
increased with a larger number of couplings.
At the University of North Carolina (UNC) Hospitals and
Clinics, approximately 125 hazardous CSPs are prepared daily,
which is associated with a $20 million annual expense. It is
imperative to manage and control the costs associated with drug
preparation through managing contract, improving drug utili-
zation, and streamlining the steps involved in preparation.
The objectives of this study were first to determine the cost
of medications discarded at 6 hours and what savings could be
potentially achieved if the BUD were extended to 24, 36, 48,
and 72 hours. In addition, the study also sampled and cultured
the contents of the vials of both active drugs and controls at 6,
24, 48, and 72 hours and 7 and 14 days to determine the
presence of microbiologic contamination and speciation, if
found.
Methods
The study design included three phases: a theoretic cost model,
projecting annual drug waste calculated from 2 months of dis-
pensing history; using actual waste log data for 6 months to
calculate and forecast annual drug waste and compare this with
the projected theoretic cost model; and testing microbial con-
tamination of vials by conducting aliquot sampling after anti-
neoplastic CSP preparation of active drug or simulated CSP
preparation with trypticase soy broth (TSB).
Theoretic Model
Data from a pharmacy information system were retrieved for
March and April 2009. These data included all hazardous
CSPs, comprising doses that were prepared with MDVs and
SDVs. Hazardous medications were defined based on approved
manufacturer package inserts specifying handling requirements
and at least one of two qualifications: classified on the National
Institute for Occupational Safety and Health list or pharmacol-
ogy consistent with drugs that may be carcinogenic or muta-
genic. Nineteen drugs were selected for analysis based on two
criteria: SDV packaging and number and frequency of CSPs.
Drugs were excluded if they were MDVs based on 28-day ac-
ceptable usage or if 10 CSPs in a 2-month period were pre-
pared. The 2009 acquisition price of each drug was used to
determine cost savings with vial extension. Each CSP contained
the drug name, dose prescribed, and label print time, which was
assumed to be the drug preparation time. Vial sizes were iden-
tified that would leave the smallest amount of medication re-
maining, and the theoretic amount of drug left over (in mg or
units) could be determined after each CSP preparation. Know-
ing the label print time of the following CSP determined if the
residual drug could be used in the next CSP. If the label print
time were  6 hours, the remaining drug would be discarded.
The investigators used the combination of vials that provided
the least amount of residual waste, even if that required more
vials for preparation than might be chosen in actual practice.
This model was carried through all CSPs made for a 2-month
period.
Five additional scenarios were modeled for discarding SDVs
and remaining drugs: immediately after one CSP and 24, 36,
48, and 72 hours after initial entry. These times were deter-
mined based on the high use of items at this institution and to
potentially span a period of Friday to Monday. Respective vial
waste was calculated for each time point using previous meth-
odology. Because a 6-hour BUD for SDVs was used, potential
cost savings were calculated comparing the 6-hour model with
the 24-, 36-, 48-, and 72-hour models.
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Actual Model
One practice implemented in the UNC Department of Phar-
macy was a daily log of all hazardous vials and CSP waste that
was discarded. The theoretic model was evaluated 2 months
before this practice. This allowed assessment of vial waste with-
out the use of a theoretic model. At the end of the day, the
evening technician would log all remaining medication in
SDVs that were beyond 6 hours. Six months of data were col-
lected from June through December 2009 (excluding August
because of the opening of new facility), and the same costs from
the theoretic model were used.
Microbiologic Phase
Before the microbiologic phase, the investigator was trained in
agar plating by a certified medical technologist from the UNC
Department of Epidemiology. Ten control vials were plated at
each time point during this training. All standard operating
procedures were followed in preparing hazardous CSPs. Com-
pounding occurred in an ISO Class 5 biologic safety cabinet
within an ISO Class 7 facility.
After the 6-hour BUD, antineoplastic drug vials that had at
least 6 mL of drug remaining were sequestered for nonpatient
care use instead of being discarded. Six hours was considered
time zero for this study, because vial extension would only occur
after this time point. Additionally, culturing before compound-
ing was not performed, because it was unknown at that time
whether waste would occur. At times 6, 24, 48, and 72 hours
and 7 and 14 days, antineoplastic drug preparation was simu-
lated by removing 1 mL of active drug. The simulated prepara-
tion occurred under all hazardous medication preparation
procedures as required for compliance with USP 797. In
addition, a closed-system transfer device (PhaSeal; Carmel
Pharma) was used in each of these simulated preparations. This
is the standard process for all chemotherapy preparations. From
the 1 mL aliquot, 0.5 mL was transferred to sheep blood agar
and 0.5 mL to trypticase soy agar and then incubated for 48
hours in the epidemiology laboratory of the hospital. Each
plate was evaluated for microbiologic growth, and if de-
tected, further speciation occurred. Control vials of sterilized
TSB (known to allow bacterial growth) were used in addi-
tion to active drug. Technicians within the oncology satellite
simulated the preparation of CSPs from the control vials,
and the investigator collected the remaining vials at 6 hours.
All vials were kept at room temperature.
Results
Theoretic Model
The total cost of drugs wasted (using 2009 prices) during the
2-month study period at 6 hours was $127,784, or $766,709
annually. Discarding the vials immediately after use, as opposed
to after 6 hours, would result in an increase of $133,054 over 2
months. If regulations allowed BUD extension of SDV use to
24, 36, 48, or 72 hours, the corresponding 2-month total cal-
culated dollars discarded would be $51,195, $36,130, $32,044,
and $21,638, respectively. The respective percentages of waste
to overall drug spending would be 2.5%, 1.8%, 1.6%, and
1.1%. The annualized savings based on the overall expenses for
these medications at each of these time points would be 3.8%,
4.5%, 4.7%, and 5.3%, respectively. With regard to the pro-
jected reduction in overall amount of waste, the percentage of
milligrams or units reduced for the modeled time periods was
also calculated (Table 1).
Actual Model
Six months of waste log data for these 19 hazardous drugs
revealed a calculated cost of $385,444, or annual cost of
$770,888. The extrapolated actual cost wasted was similar to
the annualized cost of waste for the theoretic model of 19 drugs.
Microbiologic Phase
A total of 101 vials were plated across different time periods: 6,
24, 48, and 72 hours and 7 and 14 days. This included 56 active
drug vials and 45 TSB controls. The total number of microbi-
ologic samples was 606. Twelve were discarded because of in-
appropriate handling, and two were discarded at time 14 days
because of no remaining medication. Of the remaining 592
samples, 11 were found to have microbial growth or one CFU
on one of two plates. This provided an overall plate contami-
nation rate of 1.86%. Table 2 lists the different time points and
the detection of positive samples.
Positive bacterial cultures were speciated; a summary of the
organism and number of colonies is found in Table 3. All pos-
itive samples were single isolates, and all of the identified organ-
isms are considered environmental contaminants. Zero
follow-up samples were positive for either active drug or con-
Table 1. Percent Change of Recovered Drug Associated With














Alemtuzumab 23.06 23.06 16.06 7.67 7.67 7.67
Bevacizumab 8.62 6.23 1.18 0.64 0.64 0.31
Bleomycin 34.05 31.60 23.06 23.06 23.06 23.06
Bortezomib 36.89 27.09 11.90 8.07 8.07 8.07
Busulfan 6.94 6.94 6.94 4.67 4.67 4.67
Cyclophosphamide 33.40 9.75 1.95 1.64 1.03 0.10
Cytarabine 62.83 26.84 8.84 5.08 5.08 1.83
Docetaxel 14.21 3.45 0.44 0.44 0.44 0.29
Gemcitabine 12.21 3.00 0.43 0.35 0.17 0.13
Ifosfamide 31.36 28.24 19.04 14.67 12.30 9.79
Infliximab 1.39 1.39 1.23 0.46 0.46 0.15
Irinotecan 10.81 7.38 3.35 3.03 2.70 1.38
Methotrexate (pf) 34.84 16.83 11.56 9.47 8.93 7.56
Oxaliplatin 12.42 6.65 2.46 1.58 1.58 1.28
Pemetrexed 17.13 11.60 10.41 10.41 9.18 5.29
Rituximab 11.70 4.05 0.82 0.51 0.27 0.19
Topotecan 40.63 22.40 10.94 7.80 5.58 3.24
Vincristine 14.58 4.48 1.20 0.99 0.56 0.13
Vinorelbine 11.07 11.07 11.07 10.17 10.17 10.17
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trols. In addition, positive samples were found in drugs dem-
onstrated to inhibit microbiologic growth.12,13
Discussion
The results demonstrate that adherence to a 6-hour BUD for
SDVs has significant economic implications for the drug bud-
get of this hospital. Expanding those costs to similar organiza-
tions demonstrates that there could be significant cost savings if
the BUD could be safely extended beyond 6 hours. These cost
savings were consistent across both the theoretic and actual
drug models.
A plate contamination rate of 1.86% was noted for the var-
ious tested scenarios. Although this number could be concern-
ing, it is important to critically analyze the reported data and
recognize that this is a surrogate end point and not the final
CSP.
Each of the detected speciated organisms is associated with
exogenous contamination (eg, air, skin). Importantly, the pro-
cess of transferring the aliquot in the syringe to the agar plate
(surrogate end point) required opening of the CSTD and could
have lead to introduction of contamination. These steps are not
consistent with the usual process of preparing a CSP, in which
a closed system is used throughout the whole process. However,
the investigators wanted to measure the contamination in the
vial, and this was determined to be the best method for this.
Further evaluation of the data demonstrated that there were no
subsequent positives in any samples. If a growth medium were
truly inoculated, one would expect microbial growth over time
and the following aliquot to be positive.
One study analyzing the contamination rate of pharmacy
CSPs documented a contamination rate of 0.3% when sterile
gloves were used with repeated disinfection.14 As opposed to
plating an aliquot on an agar plate, this study used Valiteq
Aseptic Technique Validation System (Lab Safety Corporation,
Des Moines, IL). A positive sample (failed test) is a cloudy or
turbid growth medium. Interpretation of results requires visual
examination of the sample, which requires hundreds to thou-
sands of colonies. In our study, all samples were single isolates
and would not have been detected as a contaminated CSP using
the mentioned methodology.
One study that tested the contamination of the material for
wrapping sterile items further supports the idea that contami-
nation could have been introduced through the plating process.
From a known sterile item, the investigators detected a plate
contamination rate of 1.7%.15 The assumption is that exposing
a microbiologic plate to the atmosphere and swabbing an item
could introduce contamination to the plate.
The study conditions included USP 797 recommenda-
tions including an ISO Class 5 environment, physical controls
(eg, biologic safety cabinets), and employee training in the
preparation of CSPs. In addition, a CSTD was used for all
preparations (PhaSeal; Carmel Pharma). Until more studies are
conducted, the authors do not feel comfortable using BUD
extension with a different physical environment or CSTDs. In
addition, it is important to note that the vials tested were SDVs
and were approved by the US Food and Drug Administration
and labeled in that manner, and the patient population receiv-
ing those preparations was immunocompromised. Although
the cost savings is substantial, and the numerous drug shortages
that would somewhat be relieved if all medication in the vial
could be used for patient care, USP 797 is the standard by
which all CSPs should prepared. However, all guidelines need
to be evidence based, and we are aware of no known studies that
document the adverse effects of extended BUDs in a controlled
environment.
Medicare does allow for billing of the discarded remainder
drug. This is only allowed for drugs and biologics covered by
Medicare Part B when the patient is located in physician offices,
hospital outpatient clinics, and other covered outpatient set-
tings.16 Challenges do exist when following this regulation, in-
cluding exclusion of inpatient usage (if medications for both
types of patients are prepared in the same location) and the need
for proper record keeping for audit purposes. Although al-
lowable, this process still transfers costs back to the federal
government, because the discarded medication is not used
for patient care.
There are potential limitations to this type of study. When
calculating the theoretic drug costs, it was assumed that the
medications were compounded at the label print time and that







15 Oxaliplatin 6 hours 1 Micrococcus sp
20 Ifosfamide 6 hours 1 Bacillus sp
20 Ifosfamide 48 hours 1 Moraxella
21 Cyclophosphamide 24 hours 1 Bacillus sp
30 Doxorubicin 24 hours 1 Bacillus sp
37 Control vial 72 hours 1 Bacillus sp
62 Control vial 7 days 1 Bacillus sp
66 Control vial 72 hours 1 Bacillus sp
86 Control vial 72 hours 1 Bacillus sp
86 Control vial 14 days 1 Micrococcus sp
110 Cidofovir 7 days 1 Micrococcus sp
Table 2. Positive Samples Per Time Period
Sample 6 Hours 24 Hours 48 Hours 72 Hours 7 Days 14 Days Total Overall Rate (%)
Active drug (n  322) 2 2 1 0 1 0 6 1.86
TSB control (n  270) 0 0 0 3 1 1 5 1.85
Total (n  592) 2 2 1 3 2 1 11 1.86
Abbreviation: TSB, trypticase soy broth.
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the vial selection for compounding was selected with the aim of
using the least amount of waste. It was also essential that the
opened vials were used first. Finally, the waste log data relied on
the process of a technician usually inspecting the vial to deter-
mine the amount remaining as opposed to drawing the volume
up in a syringe.
In conclusion, waste associated with implementation of the
USP 797 SDV 6-hour BUD recommendation is substan-
tial. Our theoretic analysis demonstrated that more than
$766,000 is being discarded annually, and our waste log reiter-
ates this with an annual cost of $770,888. The evaluation of
extending vial life beyond 6 hours was demonstrated with a
microbiologic study. A plate contamination rate of 1.86% was
detected, with all positive samples having a single isolate. The
speciated organisms were all consistent with exogenous con-
tamination, and subsequent sampling of positive vials yielded
no growth.
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